---
pattern: 6
type: failure
name: Formulaic "Challenges and Prospects"
pack: en-content
language: en
---

# Pattern 6 (en): Formulaic "Challenges and Prospects" — Failure Case (False Positive)

## Input Text

> The biggest risk to the launch is the FDA approval timeline. The average review period for this drug class is 14 months, and two of the five pending applications were filed before 2022 with no decision date yet. If U.S. approval is not granted by Q3, the company plans to redirect Phase III trials to the EU under the EMA's accelerated pathway. Meanwhile, the existing patent expires in 2028, which limits the window for return on investment.

## Expected Output

> (No correction — Pattern 6 should not fire on this text)

## Applied Pattern

- Pattern 6 (Formulaic "Challenges and Prospects"): The text acknowledges challenges (FDA delays, patent expiration) and includes a forward-looking contingency plan, which could superficially resemble the challenges-then-optimism formula.

## Judgment

**Failure (false positive)** — The exclusion condition states that "genuine uncertainty expressed with specific caveats" is acceptable — "precision makes it acceptable." Every challenge here is specific: a named regulatory body (FDA), a concrete timeline (14 months, Q3, 2028), quantified pending applications (five, two pre-2022), and a named alternative pathway (EMA accelerated). The contingency plan ("redirect to EU") is a concrete operational decision, not vague optimism. There is no "bright future" or "poised for growth" language. This is factual risk analysis, not the AI challenges-and-prospects formula.
